Empowering Pharmacists in Heartburn Management: Practical Insights for OTC Treatment and Self-Care
Abstract
1. Introduction
2. Methodology
3. Results and Discussion
3.1. Epidemiology and Risk Factors of Heartburn
Drug Class and Medications | Mechanism of Heartburn Adverse Effects | Description of Incidence | Clinical Implications | References |
---|---|---|---|---|
NSAIDs (e.g., diclofenac, aspirin, ibuprofen) | Direct topical mucosal irritancy + systemic prostaglandin inhibition → acid-mediated injury adjacent to lower esophageal sphincter (LES) | Heartburn reported to occur in up to 1/3 of patients utilizing NSAIDs | Analgesia, anti-inflammation | [37,38,39] |
Antibiotics (e.g., tetracyclines including doxycycline, clindamycin, amoxicillin, metronidazole, fluoroquinolones) | Low pH may irritate esophagus, resulting in dyspepsia and heartburn symptoms; drug-induced esophagitis | Incidence varies with medication; tetracyclines implicated in nearly 70% of all reported cases of drug-induced esophageal ulceration | Acne, atypical respiratory & zoonotic infections | [40,41] |
Bisphosphonates (e.g., alendronate, risedronate, ibandronate) | Topical irritant to the esophagus, may induce esophageal Inflammation and damage; drug-induced esophagitis | Regurgitation and heartburn are reported to occur in more than 60% of patients. | Osteoporosis, Paget’s disease | [42] |
Asthma treatment (e.g., theophylline, corticosteroids) | Theophylline use causes relaxation of LES and stimulation of gastric acid secretion, whereas systemic corticosteroids may increase stomach acid, affect the LES tone, and cause gastric irritation | Heartburn was reported in 73% (11 of 15) of subjects receiving theophylline, compared to 1 of 9 in the placebo group. | Bronchodilator for asthma | [43,44] |
GLP1-RAs (e.g., liraglutide, semaglutide, exentide, dulaglutide) | Delaying gastric emptying, increasing intragastric pressure, and promoting transient relaxation of the LES | Dyspepsia reported to occur in 4–10% of adults receiving liraglutide, in 3–9% of adults receiving subcutaneous semaglutide, in 3–7% of adults receiving exenatide, and in 4–6% of adults receiving dulaglutide | T2DM and weight management | [45,46,47,48,49,50] |
Factor | Description | References |
---|---|---|
Obesity |
| [51,52] |
High-fat diet |
| [53] |
Tobacco smoking |
| [54] |
Alcohol consumption |
| [55] |
Pregnancy |
| [56] |
Stress |
| [57] |
Gender |
| [54] |
Age |
| [58] |
Hiatal hernia |
| [59] |
3.2. Pathophysiology and Symptoms of Heartburn
3.3. The Pharmacist’s Role in Heartburn Self-Diagnosis
Questions |
---|
What is the age of the patient? |
What is the gender of the patient? |
What symptom(s) is the patient experiencing?
|
How frequently do the symptoms occur?
|
When does the patient experience heartburn?
|
Does the patient experience heartburn after lying down for 1 to 3 h after eating?
|
Has the patient previously tried lifestyle changes or medications? How did they affect patient’s symptoms? |
Referral criteria for further medical evaluation Pharmacists should refer patients for further medical evaluation, in lieu of self-care, if any of the following red flag symptoms or clinical considerations are present:
|
3.4. Heartburn Treatment Options
3.4.1. Dietary and Lifestyle Modifications
- (a)
- Avoidance of foods that may precipitate acid reflux
- (b)
- Avoidance of acidic foods that irritate the esophagus
- (c)
- Actions to reduce esophageal acid exposure
- (d)
- Medication review for drugs contributing to heartburn symptoms
3.4.2. OTC Medications
- (a)
- Antacids
- (b)
- Histamine-2-Receptor Antagonists (H2RAs)
- (c)
- Proton Pump Inhibitors (PPIs)
Antacids | Histamine-2-Receptor Antagonists (H2RAs) | Proton Pump Inhibitors (PPIs) | |||||||
---|---|---|---|---|---|---|---|---|---|
Calcium salts | Sodium salts | Magnesium salts | Aluminum salts | Cimetidine | Famotidine | Omeprazole | Esomeprazole | Lansoprazole | |
Maximum daily nonprescription dosage | 160 mEq | 200 mEq (≤60 years old) and 100 mEq (>60 years or older) | 50 mEq | NA | 200–400 mg | 40 mg | 20 mg | 20 mg | 15 mg |
Frequency | Varies based on product and formulation; used not more than 14 days for self-management of heartburn symptoms | Once a day 30–60 min before the first meal; used for no longer than 14 days for self-management of heartburn symptoms | |||||||
Side effects | Constipation, flatulence, systemic alkalosis, hypercalcemia, renal stones | Flatulence, gastric distension, systemic alkalosis and sodium overload with prolonged use | Diarrhea, hypermagnesemia, renal stones | Constipation, intestinal obstruction, hypophosphatemia | Diarrhea headache, hormonal imbalance | Fever, asthenia, fatigue, palpitations, elevated liver enzymes | Headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence | Headache, diarrhea, nausea, flatulence, abdominal pain, constipation, and dry mouth | Diarrhea, abdominal pain, nausea, and constipation |
Drug interaction | Reduced absorption of tetracyclines due to chelation with polyvalent cations (Ca2+, Mg2+, Al3+) Decreased bioavailability of fluoroquinolones (e.g., ciprofloxacin) by insoluble complex formation Lower serum concentration of bisphosphonates (e.g., alendronate): due to impaired absorption Poor dissolution of ketoconazole in elevated gastric pH thereby reduced efficacy Decreased absorption of HIV Protease Inhibitors (e.g., atazanavir) due to increased gastric pH Reduced bioavailability of dasatinib and imatinib due to pH-dependent solubility Chelation with antacid cations leads to decreased systemic exposure of eltrombopag Altered permeability and absorption depending of sulfonylureas based on antacid type and gastric pH | Elevated plasma level of phenytoin and risk of toxicity Increased serum concentration of theophylline, with potential CNS and cardiac side effects Prolonged sedation caused by benzodiazepines (e.g., diazepam) due to reduced metabolism Cimetidine reduced the renal clearance of several medications (e.g., procainamide, quinidine, propranolol, verapamil, others) Famotidine may contribute to QTc prolongation particularly when used with other QTc prolongation drugs, or in those with poor kidney function | Reduced efficacy of clopidogrel due to CYP2C19 inhibition Poor absorption of antiretrovirals due to increase in gastric pH Lower bioavailability of antifungals due to acidic stomach Increased serum concentration of antiepileptics Impaired absorption of iron supplements Reduced clearance and increase associated toxicity risk due to methotrexate Lansoprazole, has been associated with QTc interval prolongation in ICU patients, warranting caution with other QTc-prolonging drugs. | ||||||
Warnings | Ask a healthcare professional before use if you have kidney stone or on a calcium-restricted diet | Do not use if allergic to cimetidine or other acid reducers | Do not use if allergic to famotidine or other acid reducers | -Clostridioides difficile associated diarrhea -Acute tubular nephritis and risk of fractures with long term therapy -Known hypersensitivity to substituted benzimidazoles or any component of the formulation | |||||
Contraindications * | |||||||||
Renal Impairment | No | Yes | Yes | Yes | No | Yes | No | No | No |
Hepatic Impairment | No | Yes | No | No | No | No | Yes | Yes | Yes |
Other considerations for use ** | -Patients with hypercalcemia, hypercalciuria, nephrocalcinosis, and nephrolithiasis -Patients on a low-phosphate diet | -Patients on a sodium- restricted diet, e.g., those with hypertension or congestive heart failure | -Patients with severe diarrhea -Patients with neuromuscular disease such as myasthenia gravis | -Patients with constipation | -Patient with pain in swallowing food, vomiting with blood, or black stools or chest pain or lightheadedness, sweating or dizziness |
3.5. The Role of the Pharmacist in Heartburn Management
3.5.1. Information Collection and Symptom Assessment
3.5.2. Lifestyle Advice
3.5.3. Guidance on OTC Medication Selection and Use
3.5.4. Safety Monitoring
3.6. Special Groups
4. Conclusions
5. Limitations and Future Directions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Katz, P.O.; Dunbar, K.B.; Schnoll-Sussman, F.H.; Greer, K.B.; Yadlapati, R.; Spechler, S.J. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am. J. Gastroenterol. 2022, 117, 27–56. [Google Scholar] [CrossRef]
- Fass, R.; Zerbib, F.; Gyawali, C.P. AGA Clinical Practice Update on Functional Heartburn: Expert Review. Gastroenterology 2020, 158, 2286–2293. [Google Scholar] [CrossRef] [PubMed]
- McRories, J.W., Jr. Heartburn: Lifestyle Modifications and Over-the-Counter Medications. Nutr. Today 2018, 53, 18–25. [Google Scholar] [CrossRef]
- Garg, V.; Narang, P.; Taneja, R. Antacids Revisited: Review on Contemporary Facts and Relevance for Self-Management. J. Int. Med. Res. 2022, 50, 3000605221086457. [Google Scholar] [CrossRef] [PubMed]
- Yuen, E.; Romney, M.; Toner, R.W.; Cobb, N.M.; Katz, P.O.; Spodik, M.; Goldfarb, N.I. Prevalence, knowledge and care patterns for gastro-oesophageal reflux disease in United States minority populations. Aliment. Pharmacol. Ther. 2010, 32, 645–654. [Google Scholar] [CrossRef]
- MacFarlane, B. Management of Gastroesophageal Reflux Disease in Adults: A Pharmacist’s Perspective. Integr. Pharm. Res. Pract. 2018, 7, 41–52. [Google Scholar] [CrossRef]
- Wang, R.-H. From Reflux Esophagitis to Barrett’s Esophagus and Esophageal Adenocarcinoma. World. J. Gastroenterol. 2015, 21, 5210–5219. [Google Scholar] [CrossRef]
- Kahrilas, P.J.; Howden, C.W.; Wernersson, B.; Denison, H.; Nuevo, J.; Gisbert, J.P. Impact of Persistent, Frequent Regurgitation on Quality of Life in Heartburn Responders Treated with Acid Suppression: A Multinational Primary Care Study. Aliment Pharmacol. Ther. 2013, 37, 1005–1010. [Google Scholar] [CrossRef]
- Gerson, L.B.; Fass, R. A Systematic Review of the Definitions, Prevalence, and Response to Treatment of Nocturnal Gastroesophageal Reflux Disease. Clin. Gastroenterol. Hepatol. 2009, 7, 372–378, quiz 367. [Google Scholar] [CrossRef]
- Lee, S.-W.; Lien, H.-C.; Lee, T.-Y.; Yang, S.-S.; Yeh, H.-J.; Chang, C.-S. Heartburn and Regurgitation Have Different Impacts on Life Quality of Patients with Gastroesophageal Reflux Disease. Worsld J. Gastroenterol. 2014, 20, 12277–12282. [Google Scholar] [CrossRef]
- Antunes, C.; Aleem, A.; Curtis, S.A. Gastroesophageal Reflux Disease (Archived); StatPearls Publishing: Treasure Island, FL, USA, 2023. [Google Scholar]
- Gorgojo-Martínez, J.J.; Mezquita-Raya, P.; Carretero-Gómez, J.; Castro, A.; Cebrián-Cuenca, A.; Torres-Sánchez, A.d.; García-de-Lucas, M.D.; Núñez, J.; Obaya, J.C.; Soler, M.J.; et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J. Clin. Med. 2022, 12, 145. [Google Scholar] [CrossRef] [PubMed]
- Wharton, S.; Davies, M.; Dicker, D.; Lingvay, I.; Mosenzon, O.; Rubino, D.M.; Pedersen, S.D. Managing the Gastrointestinal Side Effects of GLP-1 Receptor Agonists in Obesity: Recommendations for Clinical Practice. Postgrad. Med. 2022, 134, 14–19. [Google Scholar] [CrossRef] [PubMed]
- Liu, B.D.; Udemba, S.C.; Liang, K.; Tarabichi, Y.; Hill, H.; Fass, R.; Song, G. Shorter-Acting Glucagon-like Peptide-1 Receptor Agonists Are Associated with Increased Development of Gastro-Oesophageal Reflux Disease and Its Complications in Patients with Type 2 Diabetes Mellitus: A Population-Level Retrospective Matched Cohort Study. Gut 2024, 73, 246–254. [Google Scholar] [CrossRef]
- Noguchi, Y.; Katsuno, H.; Ueno, A.; Otsubo, M.; Yoshida, A.; Kanematsu, Y.; Sugita, I.; Esaki, H.; Tachi, T.; Tsuchiya, T.; et al. Signals of Gastroesophageal Reflux Disease Caused by Incretin-Based Drugs: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database. J. Pharm. Health Care Sci. 2018, 4, 15. [Google Scholar] [CrossRef]
- Li, Z.-T.; Ji, F.; Han, X.-W.; Wang, L.; Yue, Y.-Q.; Wang, Z.-G. The Role of Gastroesophageal Reflux in Provoking High Blood Pressure Episodes in Patients with Hypertension. J. Clin. Gastroenterol. 2018, 52, 685–690. [Google Scholar] [CrossRef]
- Waring, J.P. Questions and Answers About PPI Medications and GERD. Available online: https://iffgd.org/wp-content/uploads/512-Questions-and-Answers-about-PPI-Medications-and-GERD-.pdf (accessed on 20 May 2025).
- Saleem, F.; Sharma, A. Drug-Induced Esophagitis; StatPearls Publishing: Treasure Island, FL, USA, 2023. [Google Scholar]
- Mokhtare, M.; Chaharmahali, A.; Bahardoust, M.; Ghanbari, A.; Sarveazad, A.; Naghshin, R.; Abbaskhanidavanloo, F. The Effect of Adding Duloxetine to Lansoprazole on Symptom and Quality of Life Improvement in Patients with Gastroesophageal Reflux Diseases: A Randomized Double-Blind Clinical Trial. J. Res. Med. Sci. 2021, 26, 4. [Google Scholar] [CrossRef]
- Vakil, N.; Zanten, S.V.v.; Kahrilas, P.; Dent, J.; Jones, R.; Global Consensus Group. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am. J. Gastroenterol. 2006, 101, 1900–1920, quiz 1943. [Google Scholar] [CrossRef]
- DB6. CHC Sales—Gastrointestinals. Available online: https://www.db6.nicholashall.com/report.aspx?majorcategoryid=1003 (accessed on 28 March 2024).
- Simonson, W. Implications of Over-the-Counter Proton Pump Inhibitors for Patient Counseling by Pharmacists. Am. J. Ther. 2013, 20, 676–684. [Google Scholar] [CrossRef]
- Attitudes and Beliefs About the Use of Over-the-Counter Medicines: A Dose of Reality; A National Survey of Consumers and Health Professional. Available online: https://www.bemedwise.org/wp-content/uploads/2019/12/final_survey.pdf (accessed on 20 May 2025).
- Boardman, H.F.; Heeley, G. The Role of the Pharmacist in the Selection and Use of Over-the-Counter Proton-Pump Inhibitors. Int. J. Clin. Pharm. 2015, 37, 709–716. [Google Scholar] [CrossRef]
- Bundeff, A.W.; Zaiken, K. Impact of Clinical Pharmacists’ Recommendations on a Proton Pump Inhibitor Taper Protocol in an Ambulatory Care Practice. J. Manag. Care Spec. Pharm. 2013, 19, 325–333. [Google Scholar] [CrossRef]
- Hughes, G.J.; Belgeri, M.T.; Perry, H.M. The Impact of Pharmacist Interventions on the Inappropriate Use of Acid-Suppression Therapy. Consult. Pharm. 2011, 26, 485–490. [Google Scholar] [CrossRef]
- Baethge, C.; Goldbeck-Wood, S.; Mertens, S. SANRA-a Scale for the Quality Assessment of Narrative Review Articles. Res. Integr. Peer Rev. 2019, 4, 5. [Google Scholar] [CrossRef] [PubMed]
- Shaqran, T.M.; Ismaeel, M.M.; Alnuaman, A.A.; Ahmad, F.A.A.; Albalawi, G.A.; Almubarak, J.N.; AlHarbi, R.S.; Alaqidi, R.S.; AlAli, Y.A.; Alfawaz, K.S.; et al. Epidemiology, Causes, and Management of Gastro-Esophageal Reflux Disease: A Systematic Review. Cureus 2023, 15, e47420. [Google Scholar] [CrossRef] [PubMed]
- Hachem, C.; Shaheen, N.J. Diagnosis and Management of Functional Heartburn. Am. J. Gastroenterol. 2016, 111, 53–61, quiz 62. [Google Scholar] [CrossRef]
- Zerbib, F. Differential Diagnosis of Heartburn. In WGO Handbook on HEARTBURN: A Global Perspective; WGO Foundation: Milwaukee, WI, USA, 2015. [Google Scholar]
- Hunt, R.; Quigley, E.; Abbas, Z.; Eliakim, A.; Emmanuel, A.; Goh, K.-L.; Guarner, F.; Katelaris, P.; Smout, A.; Umar, M.; et al. Coping with Common Gastrointestinal Symptoms in the Community: A Global Perspective on Heartburn, Constipation, Bloating, and Abdominal Pain/Discomfort May 2013. J. Clin. Gastroenterol. 2014, 48, 567–578. [Google Scholar] [CrossRef]
- Almario, C.V.; Ballal, M.L.; Chey, W.D.; Nordstrom, C.; Khanna, D.; Spiegel, B.M.R. Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of over 71,000 Americans. Am. J. Gastroenterol. 2018, 113, 1701–1710. [Google Scholar] [CrossRef]
- Yamasaki, T.; Hemond, C.; Eisa, M.; Ganocy, S.; Fass, R. The Changing Epidemiology of Gastroesophageal Reflux Disease: Are Patients Getting Younger? J. Neurogastroenterol. Motil. 2018, 24, 559–569. [Google Scholar] [CrossRef]
- Taraszewska, A. Risk Factors for Gastroesophageal Reflux Disease Symptoms Related to Lifestyle and Diet. Rocz. Panstw. Zakl. Hig. 2021, 72, 21–28. [Google Scholar] [CrossRef]
- Wei, T.-Y.; Hsueh, P.-H.; Wen, S.-H.; Chen, C.-L.; Wang, C.-C. The Role of Tea and Coffee in the Development of Gastroesophageal Reflux Disease. Tzu Chi Med. J. 2019, 31, 169–176. [Google Scholar] [CrossRef]
- Oliveria, S.A.; Christos, P.J.; Talley, N.J.; Dannenberg, A.J. Heartburn Risk Factors, Knowledge, and Prevention Strategies: A Population-Based Survey of Individuals with Heartburn. Arch. Intern. Med. 1999, 159, 1592–1598. [Google Scholar] [CrossRef][Green Version]
- Abdi, S.; Masbough, F.; Nazari, M.; Abbasinazari, M. Drug-Induced Esophagitis and Helpful Management for Healthcare Providers. Gastroenterol. Hepatol. Bed Bench 2022, 15, 219–224. [Google Scholar] [CrossRef]
- Ruszniewski, P.; Soufflet, C.; Barthélémy, P. Nonsteroidal Anti-Inflammatory Drug Use as a Risk Factor for Gastro-Oesophageal Reflux Disease: An Observational Study. Aliment. Pharmacol. Ther. 2008, 28, 1134–1139. [Google Scholar] [CrossRef]
- Tai, F.W.D.; McAlindon, M.E. Non-Steroidal Anti-Inflammatory Drugs and the Gastrointestinal Tract. Clin. Med. 2021, 21, 131–134. [Google Scholar] [CrossRef]
- Angelette, A.L.; Rando, L.L.; Wadhwa, R.D.; Barras, A.A.; Delacroix, B.M.; Talbot, N.C.; Ahmadzadeh, S.; Shekoohi, S.; Cornett, E.M.; Kaye, A.M.; et al. Tetracycline-, Doxycycline-, Minocycline-Induced Pseudotumor Cerebri and Esophageal Perforation. Adv. Ther. 2023, 40, 1366–1378. [Google Scholar] [CrossRef] [PubMed]
- Segelnick, S.L.; Weinberg, M.A. Recognizing Doxycycline-Induced Esophageal Ulcers in Dental Practice: A Case Report and Review. J. Am. Dent. Assoc. 2008, 139, 581–585. [Google Scholar] [CrossRef]
- Mungan, Z.; Şimşek, B.P. Which Drugs Are Risk Factors for the Development of Gastroesophageal Reflux Disease? Turk. J. Gastroenterol. 2017, 28, S38–S43. [Google Scholar] [CrossRef] [PubMed]
- Berquist, W.E.; Rachelefsky, G.S.; Kadden, M.; Siegel, S.C.; Katz, R.M.; Mickey, M.R.; Ament, M.E. Effect of Theophylline on Gastroesophageal Reflux in Normal Adults. J. Allergy Clin. Immunol. 1981, 67, 407–411. [Google Scholar] [CrossRef]
- Lacy, B.E.; Mathis, C.; DesBiens, J.; Liu, M.C. The Effects of Nebulized Albuterol on Esophageal Function in Asthmatic Patients. Dig. Dis. Sci. 2008, 53, 2627–2633. [Google Scholar] [CrossRef]
- Yoon, N.M.; Cavaghan, M.K.; Brunelle, R.L.; Roach, P. Exenatide Added to Insulin Therapy: A Retrospective Review of Clinical Practice over Two Years in an Academic Endocrinology Outpatient Setting. Clin. Ther. 2009, 31, 1511–1523. [Google Scholar] [CrossRef]
- Gu, C.; Olszewski, T.; Vaezi, M.F.; Niswender, K.D.; Silver, H.J. Objective Ambulatory pH Monitoring and Subjective Symptom Assessment of Gastroesophageal Reflux Disease Show Type of Carbohydrate and Type of Fat Matter. Ther. Adv. Gastroenterol. 2022, 15, 17562848221101289. [Google Scholar] [CrossRef]
- Liraglutide (Victoza) U.S. Food and Drug Administration, Victoza (Liraglutide) Injection, for Subcutaneous Use—Prescribing Information. Novo Nordisk Inc. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf (accessed on 31 July 2025).
- Semaglutide (Ozempic) U.S. Food and Drug Administration, Ozempic (Semaglutide) Injection, for Subcutaneous Use—Prescribing Information. Novo Nordisk Inc. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf (accessed on 31 July 2025).
- Exenatide (Byetta) U.S. Food and Drug Administration, Byetta (Exenatide) Injection—Prescribing Information. AstraZeneca Pharmaceuticals LP. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021773s049lbl.pdf (accessed on 31 July 2025).
- Dulaglutide (Trulicity) U.S. Food and Drug Administration, Trulicity (Dulaglutide) Injection, for Subcutaneous Use—Prescribing Information. Eli Lilly and Company. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125469s023lbl.pdf (accessed on 31 July 2025).
- Sharara, A.I.; Rustom, L.B.O.; Daher, H.B.; Rimmani, H.H.; Shayto, R.H.; Minhem, M.; Ichkhanian, Y.; Aridi, H.; Al-Abbas, A.; Shaib, Y.; et al. Prevalence of Gastroesophageal Reflux and Risk Factors for Erosive Esophagitis in Obese Patients Considered for Bariatric Surgery. Dig. Liver Dis. 2019, 51, 1375–1379. [Google Scholar] [CrossRef] [PubMed]
- Hiramoto, B.; Redd, W.D.; Muftah, M.; Jonnadula, S.; Okwara, N.C.; Jenkins, A.; Cricco-Lizza, E.; Lee, D.J.H.; Cai, J.X.; Chan, W.W. Higher Obesity Class Is Associated with More Severe Esophageal Symptoms and Reflux Burden but Not Altered Motor Function or Contractile Reserve. Neurogastroenterol. Motil. 2024, 36, e14691. [Google Scholar] [CrossRef]
- Heidarzadeh-Esfahani, N.; Soleimani, D.; Hajiahmadi, S.; Moradi, S.; Heidarzadeh, N.; Nachvak, S.M. Dietary Intake in Relation to the Risk of Reflux Disease: A Systematic Review. Prev. Nutr. Food Sci. 2021, 26, 367–379. [Google Scholar] [CrossRef] [PubMed]
- Visnes, E.S.; Hallan, A.; Bomme, M.; Holmberg, D.; Møller-Hansen, J.; Lagergren, J.; Ness-Jensen, E. Prevalence and Risk Factors of Gastro-Oesophageal Reflux Symptoms among Adolescents, the HUNT Study. Scand. J. Gastroenterol. 2024, 59, 816–820. [Google Scholar] [CrossRef]
- Ness-Jensen, E.; Lagergren, J. Tobacco Smoking, Alcohol Consumption and Gastro-Oesophageal Reflux Disease. Best. Pract. Res. Clin. Gastroenterol. 2017, 31, 501–508. [Google Scholar] [CrossRef]
- Madanick, R.D. Gastroesophageal Reflux Disease in Pregnancy. In GI and Liver Disease During Pregnancy; CRC Press: Boca Raton, FL, USA, 2012; pp. 1–11. [Google Scholar]
- Deepak, K.; Pragathi, W.; Prashanth, P. A Comprehensive Analysis of Patients with Abdominal Symptoms and Associated Risk Factors. Eur. J. Cardiovasc. Med. 2024, 14, 701–710. [Google Scholar]
- Sadeghi, A.; Boustani, P.; Mehrpour, A.; Asgari, A.A.; Sharafkhah, M.; Yazdanbod, A.; Somi, M.H.; Nejatizadeh, A.; Moradpour, F.; Rezaeian, M.; et al. Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Iran: A Cross-Sectional Analysis from the PERSIAN Cohort. PLoS ONE 2024, 19, e0306223. [Google Scholar] [CrossRef] [PubMed]
- Quach, D.T.; Pham, Q.T.T.; Tran, T.L.T.; Vu, N.T.H.; Le, Q.D.; Nguyen, D.T.N.; Dang, N.L.B.; Le, H.M.; Le, N.Q. Clinical Characteristics and Risk Factors of Gastroesophageal Reflux Disease in Vietnamese Patients with Upper Gastrointestinal Symptoms Undergoing Esophagogastroduodenoscopy. JGH Open 2021, 5, 580–584. [Google Scholar] [CrossRef]
- Ustaoglu, A.; Sawada, A.; Lee, C.; Lei, W.-Y.; Chen, C.-L.; Hackett, R.; Sifrim, D.; Peiris, M.; Woodland, P. Heartburn Sensation in Nonerosive Reflux Disease: Pattern of Superficial Sensory Nerves Expressing TRPV1 and Epithelial Cells Expressing ASIC3 Receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 2021, 320, G804–G815. [Google Scholar] [CrossRef]
- Ang, D.; Sifrim, D.; Tack, J. Mechanisms of Heartburn. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008, 5, 383–392. [Google Scholar] [CrossRef]
- Ying, L.N.; Sun, Y.; Cui, L.Y.; Zhang, Z.Y.; Li, R.F.; Zhang, J. Recent Advances in the Knowledge of the Mechanism of Reflux Hypersensitivity. Scand. J. Gastroenterol. 2024, 59, 518–523. [Google Scholar] [CrossRef]
- Mokrowiecka, A.; Bartoszek, A.; Fabisiak, A.; Wróbel, A.; Fichna, J.; Wierzchniewska-Ławska, A.; Jacenik, D.; Małecka-Wojciesko, E. The Expression of F2RL1, P2RX2, P2RX3 and P2RY2 in the Esophagus of Patients with Gastroesophageal Reflux Disease and Their Relationship to Reflux Symptoms-A Pilot Study. J. Clin. Med. 2025, 14, 1884. [Google Scholar] [CrossRef]
- Clarrett, D.M.; Hachem, C. Gastroesophageal Reflux Disease (GERD). Mo. Med. 2018, 115, 214–218. [Google Scholar]
- Jones, R.; Ballard, K. Healthcare Seeking in Gastro-Oesophageal Reflux Disease: A Qualitative Study. Eur. J. Gastroenterol. Hepatol. 2008, 20, 269–275. [Google Scholar] [CrossRef] [PubMed]
- DeVault, K.R. Heartburn, Regurgitation, and Chest Pain. In Practical Gastroenterology and Hepatology Board Review Toolkit, 2nd ed.; Wiley: Hoboken, NJ, USA, 2016; pp. 46–51. [Google Scholar]
- Calleja, J.L.; Bixquert, M.; Maldonado, J. Impact of Nocturnal Heartburn on Quality of Life, Sleep, and Productivity: The SINERGE Study. Dig. Dis. Sci. 2007, 52, 2858–2865. [Google Scholar] [CrossRef] [PubMed]
- NIDDK, Diagnosis of GER & GERD. Available online: https://www.niddk.nih.gov/health-information/digestive-diseases/acid-reflux-ger-gerd-adults/diagnosis (accessed on 20 May 2025).
- University of Saskatchewan. PHARMACIST ASSESSMENT—Gastroesophageal Reflux Disease (GERD). Available online: https://medsask.usask.ca/sites/medsask/files/2023-04/BC-GERD-PAR.pdf (accessed on 3 October 2024).
- Ebell, M.H. Diagnosis of Gastroesophageal Reflux Disease. Am. Fam. Physician 2010, 81, 1278. [Google Scholar] [PubMed]
- Berardi, R.R.; Desimone, E.M.; Newton, G.D. (Eds.) Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care; American Pharmaceutical Association: Washington, DC, USA, 2002. [Google Scholar]
- Zhang, M.; Hou, Z.-K.; Huang, Z.-B.; Chen, X.-L.; Liu, F.-B. Dietary and Lifestyle Factors Related to Gastroesophageal Reflux Disease: A Systematic Review. Ther. Clin. Risk Manag. 2021, 17, 305–323. [Google Scholar] [CrossRef]
- Kahrilas, P.J.; Shaheen, N.J.; Vaezi, M.F. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Gastroenterology 2008, 135, 1383–1391. [Google Scholar] [CrossRef]
- Wu, K.-L.; Kuo, C.-M.; Yao, C.-C.; Tai, W.-C.; Chuah, S.-K.; Lim, C.-S.; Chiu, Y.-C. The Effect of Dietary Carbohydrate on Gastroesophageal Reflux Disease. J. Formos. Med. Assoc. 2018, 117, 973–978. [Google Scholar] [CrossRef]
- Pan, J.; Cen, L.; Chen, W.; Yu, C.; Li, Y.; Shen, Z. Alcohol Consumption and the Risk of Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. Alcohol. Alcohol. 2019, 54, 62–69. [Google Scholar] [CrossRef]
- Herdiana, Y. Functional Food in Relation to Gastroesophageal Reflux Disease (GERD). Nutrients 2023, 15, 3583. [Google Scholar] [CrossRef] [PubMed]
- Jarosz, M.; Taraszewska, A. Risk Factors for Gastroesophageal Reflux Disease: The Role of Diet. Prz. Gastroenterol. 2014, 9, 297–301. [Google Scholar] [CrossRef]
- Khan, M.; Shah, K.; Gill, S.K.; Gul, N.; J, J.K.; Valladares, V.; Khan, L.A.; Raza, M. Dietary Habits and Their Impact on Gastroesophageal Reflux Disease (GERD). Cureus 2024, 16, e65552. [Google Scholar] [CrossRef]
- Hungin, A.P.; Yadlapati, R.; Anastasiou, F.; Bredenoord, A.J.; Serag, H.E.; Fracasso, P.; Mendive, J.M.; Savarino, E.V.; Sifrim, D.; Udrescu, M.; et al. Management Advice for Patients with Reflux-like Symptoms: An Evidence-Based Consensus. Eur. J. Gastroenterol. Hepatol. 2024, 36, 13–25. [Google Scholar] [CrossRef]
- Nachawi, N.; Rao, P.P.; Makin, V. The Role of GLP-1 Receptor Agonists in Managing Type 2 Diabetes. Cleve Clin. J. Med. 2022, 89, 457–464. [Google Scholar] [CrossRef]
- Haleon Nicorette Lozenge Dosing and Administration. Available online: https://www.haleonhealthpartner.com/en-us/respiratory-health/brands/nicotine-replacement-therapy/nicorette-lozenges/nicorette-lozenges-dosing-administration/ (accessed on 20 May 2025).
- Haleon Nicorette Gum Dosing and Administration. Available online: https://www.haleonhealthpartner.com/en-us/respiratory-health/brands/nicotine-replacement-therapy/nicorette-gum/nicorette-gum-dosing-administration/ (accessed on 20 May 2025).
- Liu, L.; Chen, J.; Wang, L.; Chen, C.; Chen, L. Association between Different GLP-1 Receptor Agonists and Gastrointestinal Adverse Reactions: A Real-World Disproportionality Study Based on FDA Adverse Event Reporting System Database. Front. Endocrinol. 2022, 13, 1043789. [Google Scholar] [CrossRef]
- Maton, P.N.; Burton, M.E. Antacids Revisited: A Review of Their Clinical Pharmacology and Recommended Therapeutic Use. Drugs 1999, 57, 855–870. [Google Scholar] [CrossRef]
- Sethi, S.; Richter, J.E. Diet and Gastroesophageal Reflux Disease: Role in Pathogenesis and Management. Curr. Opin. Gastroenterol. 2017, 33, 107–111. [Google Scholar] [CrossRef]
- Voropaiev, M.; Nock, D. Onset of Acid-Neutralizing Action of a Calcium/Magnesium Carbonate-Based Antacid Using an Artificial Stomach Model: An in Vitro Evaluation. BMC Gastroenterol. 2021, 21, 112. [Google Scholar] [CrossRef] [PubMed]
- Bennett, P.N.; Brown, M.J. Clinical Pharmacology E-Book: With STUDENTCONSULT Access; Elsevier Health Sciences: Amsterdam, The Netherlands, 2007. [Google Scholar]
- Collings, K.L.; Rodriguez-Stanley, S.; Proskin, H.M.; Robinson, M.; Miner, P.B. Clinical Effectiveness of a New Antacid Chewing Gum on Heartburn and Oesophageal pH Control. Aliment. Pharmacol. Ther. 2002, 16, 2029–2035. [Google Scholar] [CrossRef] [PubMed]
- Robinson, M.; Rodriguez-Stanley, S.; Miner, P.B.; McGuire, A.J.; Fung, K.; Ciociola, A.A. Effects of Antacid Formulation on Postprandial Oesophageal Acidity in Patients with a History of Episodic Heartburn. Aliment. Pharmacol. Ther. 2002, 16, 435–443. [Google Scholar] [CrossRef] [PubMed]
- Robinson, M.; Earnest, D.; Rodriguez-Stanley, S.; Meerveld, B.G.-V.; Jaffe, P.; Silver, M.T.; Kleoudis, C.S.; Wilson, L.E.; Murdock, R.H. Heartburn Requiring Frequent Antacid Use May Indicate Significant Illness. Arch. Intern. Med. 1998, 158, 2373–2376. [Google Scholar] [CrossRef] [PubMed]
- Richter, J.E. The Many Manifestations of Gastroesophageal Reflux Disease: Presentation, Evaluation, and Treatment. Gastroenterol. Clin. North. Am. 2007, 36, 577–599, viii–viix. [Google Scholar] [CrossRef]
- FDA. Amneal Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Nizatidine Oral Solution, 15 Mg/mL, due to Potential Levels of N-Nitrosodimethylamine (NDMA) Impurity Amounts Above the Levels Established by FDA. Available online: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-nizatidine-oral-solution-15-mgml-due#:~:text=Nizatidine%20Oral%20Solution%20is%20being,on%20results%20from%20laboratory%20tests (accessed on 3 October 2024).
- FDA. FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. Available online: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market#:~:text=The%20U.S.%20Food%20and%20Drug%20Administration%20today%20announced%20it%20is (accessed on 3 October 2024).
- Zhao, F.; Wang, S.; Liu, L.; Wang, Y. Comparative Effectiveness of Histamine-2 Receptor Antagonists as Short-Term Therapy for Gastro-Esophageal Reflux Disease: A Network Meta-Analysis. Int. J. Clin. Pharmacol. Ther. 2016, 54, 761–770. [Google Scholar] [CrossRef]
- Dhar, A.; Maw, F.; Dallal, H.J.; Attwood, S. Side Effects of Drug Treatments for Gastro-Oesophageal Reflux Disease: Current Controversies. Frontline Gastroenterol. 2022, 13, 45–49. [Google Scholar] [CrossRef]
- Pino, M.A.; Azer, S.A. Cimetidine. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
- Jung, S.B.; Nagaraja, V.; Kapur, A.; Eslick, G.D. Association between Vitamin B12 Deficiency and Long-Term Use of Acid-Lowering Agents: A Systematic Review and Meta-Analysis. Intern. Med. J. 2015, 45, 409–416. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.W.; Kayser, S.R.; Hongo, R.H.; Tseng, Z.H.; Scheinman, M.M. Famotidine and Long QT Syndrome. Am. J. Cardiol. 2004, 93, 1325–1327. [Google Scholar] [CrossRef]
- Schubert, M.L.; Peura, D.A. Control of Gastric Acid Secretion in Health and Disease. Gastroenterology 2008, 134, 1842–1860. [Google Scholar] [CrossRef]
- Ahmed, A.; Clarke, J.O. Proton Pump Inhibitors (PPI). In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
- Miner, P.B.; McKean, L.A.; Gibb, R.D.; Erasala, G.N.; Ramsey, D.L.; McRorie, J.W. Omeprazole-Mg 20.6 Mg Is Superior to Lansoprazole 15 Mg for Control of Gastric Acid: A Comparison of Over-the-Counter Doses of Proton Pump Inhibitors. Aliment Pharmacol. Ther. 2010, 31, 846–851. [Google Scholar] [CrossRef]
- Bardhan, K.D.; Müller-Lissner, S.; Bigard, M.A.; Porro, G.B.; Ponce, J.; Hosie, J.; Scott, M.; Weir, D.G.; Gillon, K.R.; Peacock, R.A.; et al. Symptomatic Gastro-Oesophageal Reflux Disease: Double Blind Controlled Study of Intermittent Treatment with Omeprazole or Ranitidine. BMJ 1999, 318, 502–507. [Google Scholar] [CrossRef]
- Lind, T.; Havelund, T.; Lundell, L.; Glise, H.; Lauritsen, K.; Pedersen, S.A.; Anker-Hansen, O.; Stubberöd, A.; Eriksson, G.; Carlsson, R.; et al. On Demand Therapy with Omeprazole for the Long-Term Management of Patients with Heartburn without Oesophagitis--a Placebo-Controlled Randomized Trial. Aliment Pharmacol. Ther. 1999, 13, 907–914. [Google Scholar] [CrossRef]
- Venables, T.L.; Newland, R.D.; Patel, A.C.; Hole, J.; Wilcock, C.; Turbitt, M.L. Omeprazole 10 Milligrams Once Daily, Omeprazole 20 Milligrams Once Daily, or Ranitidine 150 Milligrams Twice Daily, Evaluated as Initial Therapy for the Relief of Symptoms of Gastro-Oesophageal Reflux Disease in General Practice. Scand. J. Gastroenterol. 1997, 32, 965–973. [Google Scholar] [CrossRef]
- Katz, P.O.; Gerson, L.B.; Vela, M.F. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am. J. Gastroenterol. 2013, 108, 308–328, quiz 329; Erratum in Am. J. Gastroenterol. 2013, 108, 1672. [Google Scholar] [CrossRef]
- Miner, P.B.; Allgood, L.D.; Grender, J.M. Comparison of Gastric pH with Omeprazole Magnesium 20.6 Mg (Prilosec OTC) O.M. Famotidine 10 Mg (Pepcid AC) B.D. And Famotidine 20 Mg B.D. Over 14 Days of Treatment. Aliment Pharmacol. Ther. 2007, 25, 103–109. [Google Scholar] [CrossRef] [PubMed]
- Armstrong, D.; Talley, N.J.; Lauritsen, K.; Moum, B.; Lind, T.; Tunturi-Hihnala, H.; Venables, T.; Green, J.; Bigard, M.A.; Mössner, J.; et al. The Role of Acid Suppression in Patients with Endoscopy-Negative Reflux Disease: The Effect of Treatment with Esomeprazole or Omeprazole. Aliment Pharmacol. Ther. 2004, 20, 413–421. [Google Scholar] [CrossRef] [PubMed]
- Graham, D.Y.; Tansel, A. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin. Gastroenterol. Hepatol. 2018, 16, 800–808. [Google Scholar] [CrossRef] [PubMed]
- Strand, D.S.; Kim, D.; Peura, D.A. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver 2017, 11, 27–37. [Google Scholar] [CrossRef] [PubMed]
- Fan, W.; Liu, H.; Shen, Y.; Hong, K. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients. Cardiovasc. Drugs Ther. 2024, 38, 517–525. [Google Scholar] [CrossRef]
- Lespessailles, E.; Toumi, H. Proton Pump Inhibitors and Bone Health: An Update Narrative Review. Int. J. Mol. Sci. 2022, 23, 10733. [Google Scholar] [CrossRef]
- FDA. FDA Drug Safety Communication: Possible Increased Risk of Fractures of the Hip, Wrist, and Spine with the Use of Proton Pump Inhibitors. Available online: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump#:~:text=FDA%20has%20determined%20an%20osteoporosis%20and%20fracture%20warning,with%20short-term%2C%20low%20dose%20PPI%20use%20is%20unlikely (accessed on 3 October 2024).
- FDA. PRILOSEC® (Omeprazole Magnesium) for Delayed-Release Oral Suspension. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022056s023lbl.pdf (accessed on 3 October 2024).
- Sullivan, J.S.; Sundaram, S.S. Gastroesophageal Reflux. Pediatr. Rev. 2012, 33, 243–253, quiz 254. [Google Scholar] [CrossRef]
- Dettmar, P.W.; Strugala, V.; Fisher, J.; Woodcock, A. The Antacid Efficacy of Maalox in Comparison to a Range of Antacids. J. Pharm. Ther. 2019, 5, 301–325. [Google Scholar]
- Bell, J.; Dziekan, G.; Pollack, C.; Mahachai, V. Self-Care in the Twenty First Century: A Vital Role for the Pharmacist. Adv. Ther. 2016, 33, 1691–1703. [Google Scholar] [CrossRef]
- Vordenberg, S.E. Nonprescription Heartburn Medications for Adults. JAMA 2023, 330, 1499. [Google Scholar] [CrossRef]
- Sehrish, K.; Aziz, M.R.; Farhan, K.M.; Iqbal, D.M. Misconception of Heart Attack Pain with Heart Burn-How Common Is It? Pak. Heart J. 2017, 50, 89–93. [Google Scholar]
- Nakhla, N.; Houle, S.K.D.; Richard, F.; Taylor, J. Survey of community pharmacists’ opinions on drug scheduling in Ontario and Québec. J Pharm Policy Pract. 2024, 17, 2385936. [Google Scholar] [CrossRef] [PubMed]
- Altuwaijri, M. Evidence-Based Treatment Recommendations for Gastroesophageal Reflux Disease during Pregnancy: A Review. Medicine 2022, 101, e30487. [Google Scholar] [CrossRef] [PubMed]
- Ali, R.A.R.; Hassan, J.; Egan, L.J. Review of Recent Evidence on the Management of Heartburn in Pregnant and Breastfeeding Women. BMC Gastroenterol. 2022, 22, 219. [Google Scholar] [CrossRef] [PubMed]
- Phupong, V.; Hanprasertpong, T. Interventions for Heartburn in Pregnancy. Cochrane Database Syst. Rev. 2015, 15, CD011379. [Google Scholar] [CrossRef]
- Lightdale, J.R.; Gremse, D.A. Gastroesophageal Reflux: Management Guidance for the Pediatrician. Pediatrics 2013, 131, e1684–e1695. [Google Scholar] [CrossRef]
- Center for Medicare & Medicaid Services. Proton Pump Inhibitors: Use in Pediatric Patients; Center for Medicare & Medicaid Services: Baltimore, MD, USA, 2015. [Google Scholar]
- Wurtsbaugh, W.A.; Paerl, H.W.; Dodds, W.K. Nutrients, Eutrophication and Harmful Algal Blooms along the Freshwater to Marine Continuum. WIREs Water 2019, 6, e1373. [Google Scholar] [CrossRef]
- The 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J. Am. Geriatr. Soc. 2023, 71, 2052–2081. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bridgeman, M.B.; Hospattankar, A.; Siddiqui, K.; Nakhla, N. Empowering Pharmacists in Heartburn Management: Practical Insights for OTC Treatment and Self-Care. Pharmacy 2025, 13, 124. https://doi.org/10.3390/pharmacy13050124
Bridgeman MB, Hospattankar A, Siddiqui K, Nakhla N. Empowering Pharmacists in Heartburn Management: Practical Insights for OTC Treatment and Self-Care. Pharmacy. 2025; 13(5):124. https://doi.org/10.3390/pharmacy13050124
Chicago/Turabian StyleBridgeman, Mary Barna, Ashok Hospattankar, Kamran Siddiqui, and Nardine Nakhla. 2025. "Empowering Pharmacists in Heartburn Management: Practical Insights for OTC Treatment and Self-Care" Pharmacy 13, no. 5: 124. https://doi.org/10.3390/pharmacy13050124
APA StyleBridgeman, M. B., Hospattankar, A., Siddiqui, K., & Nakhla, N. (2025). Empowering Pharmacists in Heartburn Management: Practical Insights for OTC Treatment and Self-Care. Pharmacy, 13(5), 124. https://doi.org/10.3390/pharmacy13050124